(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
Some Americans say they'll go without health insurance as ACA rates spike- Flu illness count nears 5 million, with New York City among the hardest hit
- Hypothermia claims newborn in Gaza and more babies are at risk, doctor says
- Investigation reveals sperm donor passed on cancer risk to dozens of children across Europe
- Virtual Domains d: A Survey of \Inundation and Ongoing interaction Mechanics\ Computer game
- Investigating the Medical advantages of Aloe Vera
- Sheinelle Jones will cohost fourth hour of 'Today' with Jenna Bush Hager: Here's what to know about her
- Looking for a great Thanksgiving side dish recipe? These are the crowd-pleasers the Yahoo team swears by.
- France honors the victims of the Paris attacks' night of terror 10 years on
